Pharmacovigilance of gene therapy medicinal products

Abstract

Gene therapy medicinal products (GTMPs) may generate unexpected risks to public health and individual patients. Pharmacovigilance serves the purpose of detecting, assessing, understanding, and preventing adverse effects or any other medicine-related problems. This article aims to provide an overview of the significance of pharmacovigilance and particularities in the domain of gene therapy with a brief description of the European regulatory framework. Viral vectors, insertional mutagenesis, viral latency or reactivation, as well as duration and accuracy of the patient’s clinical follow-up, are some of the main concerns. Two recent examples of signals illustrate some of these safety issues. The first concerns onasemnogene abeparvovec, an adeno-associated virus-based gene replacement therapy for treating spinal muscular atrophy. This GTMP initially raised safety concerns about hepatotoxicity, cardiotoxicity, and neurotoxicity, necessitating recommendations for close monitoring. During the post-marketing period, two fatal cases of acute liver failure led the European Medicine Agency (EMA) to strengthen the recommendations for liver function monitoring. The second example pertains to betibeglogene autotemcel, a genetically modified autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with lentiviral vectors encoding the β A-T87Q-globin gene. After the report of a case of acute myeloid leukemia in a patient treated with an investigational product using the same lentiviral vector, the European Commission triggered a regulatory safety procedure. After careful assessment, the EMA’s ad hoc safety committees stated that the viral vector was unlikely to be the cause. However, due to commercial reasons, betibeglogene autotemcel was finally withdrawn from the market by the marketing authorization holder. Pharmacovigilance activities and systems continuously evolve to keep pace with advancements in new therapies and technologies. They must also address varied situations and adhere to evolving regulations. GTMPs likely stand out as one of the most demanding areas within pharmacovigilance. Therefore, their effective oversight requires the full commitment of pharmacological and clinical experts, as well as active involvement from patients, to ensure optimal outcomes.

Keywords

Gene therapy / pharmacovigilance / safety / viral vectors

References

[1] Orzetti S,Bertola A.Genetic therapy and molecular targeted therapy in oncology: safety, pharmacovigilance, and perspectives for research and clinical practice.Int J Mol Sci2022;23:3012 PMCID:PMC8951339

[2] World Health Organization. The importance of pharmacovigilance. Available from: https://www.who.int/publications-detail-redirect/10665-42493 [Last accessed on 20 Nov 2023]

[3] Kugener VF,Maynard KI.Enhancing pharmacovigilance from the US experience: current practices and future opportunities.Drug Saf2021;44:843-52. PMCID:PMC8123099

[4] EMA European Medicine Agency. Good pharmacovigilance practices. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices#final-gvp-annex-i---definitions-section [Last accessed on 20 Nov 2023]

[5] EMA European Medicine Agency. Guideline on good pharmacovigilance practices (GVP) module XV - safety communication (Rev 1). Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xv-safety-communication-rev-1_en.pdf [Last accessed on 20 Nov 2023]

[6] EMA. How the committees work. Available from: https://www.ema.europa.eu/en/committees/how-committees-work [Last accessed on 20 Nov 2023]

[7] EMA European Medicine Agency. Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products-scientific guideline. Available from: https://www.ema.europa.eu/en/guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products-scientific [Last accessed on 20 Nov 2023]

[8] EMA European Medicine Agency. Guideline on follow-up of patients administered with gene therapy medicinal products. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdf [Last accessed on 20 Nov 2023]

[9] EMA European Medicine Agency. Reflection paper on quality, non-clinical and clinical issues related to the development of recombinant adenoassociated viral vectors. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-quality-non-clinical-clinical-issues-related-development-recombinant-adeno_en.pdf [Last accessed on 20 Nov 2023]

[10] EMA European Medicine Agency. Reflection paper on management of clinical risks deriving from insertional mutagenesis. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-management-clinical-risks-deriving-insertional-mutagenesis_en.pdf [Last accessed on 20 Nov 2023]

[11] David RM.Viral vectors: the road to reducing genotoxicity.Toxicol Sci2017;155:315-25

[12] Aiuti A,de Felipe P.The committee for advanced therapies' of the European Medicines Agency reflection paper on management of clinical risks deriving from insertional mutagenesis.Hum Gene Ther Clin Dev2013;24:47-54.

[13] Wagner EF,Stewart TA.Prenatal lethalities in mice homozygous for human growth hormone gene sequences integrated in the germ line.Cell1983;35:647-55

[14] Hacein-Bey-Abina S,Lim A.Efficacy of gene therapy for X-linked severe combined immunodeficiency.N Engl J Med2010;363:355-64 PMCID:PMC2957288

[15] Riggan KA,Michie M.Evaluating the risks and benefits of genetic and pharmacologic interventions for down syndrome: views of parents.Am J Intellect Dev Disabil2020;125:1-13 PMCID:PMC7754248

[16] Day JW,Mercuri E.Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy.Drug Saf2021;44:1109-19 PMCID:PMC8473343

[17] Hinderer C,Buza EL.Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN.Hum Gene Ther2018;29:285-98 PMCID:PMC5865262

[18] Chand D,McMillan H.Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.J Hepatol2021;74:560-6

[19] Feldman AG,Dutmer CM.Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1.J Pediatr2020;225:252-8.e1 PMCID:PMC10152980

[20] NOVARTIS. Zolgensma acute liver failure update. Available from: https://www.novartis.com/news/zolgensma-acute-liver-failure-update [Last accessed on 20 Nov 2023]

[21] EMA European Medicine Agency. Pharmacovigilance risk assessment committee (PRAC) PRAC minutes on 08-11 March 2021. Available from: https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-8-11-march-2021_en.pdf [Last accessed on 20 Nov 2023]

[22] EMA European Medicine Agency. Zynteglo withdrawal of the marketing authorisation in the European Union. Available from: https://www.ema.europa.eu/en/documents/public-statement/public-statement-zynteglo-withdrawal-marketing-authorisation-european-union_en.pdf [Last accessed on 20 Nov 2023]